Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors

Abstract

The present invention relates to 5-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula wherein said “A” is a 5-7 membered heterocyclic ring as defined in the specification and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.

1 . A compound of the formula:  
       
         
           
           
               
               
           
         
         wherein said “A” is a 5-7 membered heterocyclic ring selected from the group consisting of:  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10  and R 11  is independently selected from the group consisting of hydrogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkenyl, (C 1 -C 4 )alkynyl, (C 6 -C 10 )aryl, (C 1 -C 10 )heteroaryl, (C 3 -C 8 )Cycloalkyl and (C 1 -C 10 )heterocyclyl; wherein each of said (C 1 -C 4 )alkyl, (C 6 -C 10 )aryl, (C 1 -C 10 )heteroaryl, (C 3 -C 8 )cycloalkyl and (C 1 -C 10 )heterocyclyl may be optionally substituted on any of the ring carbon atoms capable of forming an additional bond with 1-3 substituents per ring independently selected from halo, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, —CN, —OH and —NH 2 ;  
         X is (C 6 -C 10 )aryl or (C 1 -C 10 )heteroaryl;  
         Y is selected from the group consisting of a bond, oxygen, sulfur, >C═O, >SO 2 , >S═O, —CH 2 —, —CH 2 O—, O(CH 2 ) n —, —CH 2 S—, S(CH 2 ) n —, —CH 2 SO—, —CH 2 SO 2 —, SO(CH 2 ) n —,  
         —SO 2 (CH 2 ) n —, —NR 14 , —NR 14 (CH 2 ) n —, —CH 2 [N(R 14 )]—, —CH 2 (CH 2 ) n —, —CH═CH—, —C≡C—, —[N(R 14 )]—SO 2 — and —SO 2 [N(R 14 )]—;  
         n is an integer from one to four;  
         R 14  is hydrogen or  ( C 1 -C 4 )alkyl;  
         Z is selected from the group consisting of (C 6 -C 10 )aryl, (C 3 -C 8 )cycloalkyl, (C 1 -C 10 )heterocyclyl and (C 1 -C 10 )heteroaryl; wherein one or two carbon-carbon single bonds of said (C 3 -C 8 )cycloalkyl or (C 1 -C 10 )heterocyclyl may optionally be replaced by carbon-carbon double bonds;  
         wherein each of said X or Z may be independently optionally substituted on any of the ring carbon atoms capable of forming an additional bond by one or two substituents per ring independently selected from F, Cl, Br, CN, OH, (C 1 -C 4 )alkyl, (C 1 -C 4 )perfluoroalkyl, (C 1 -C 4 )perfluoroalkoxy, (C 1 -C 4 )alkoxy and (C 3 -C 8 )cycloalkyloxy;  
         G is R 15 —(CR 16 R 17 ) p —; wherein G is a substituent on any ring carbon atom of Z capable of forming an additional bond and is oriented at a position other than alpha to the point of attachment of the Z ring to Y;  
         p is an integer from 0 to 4;  
         R 15  is independently selected from the group consisting of halo, —CN, —NO 2 , OH, (C 1 -C 4 )alkenyl, (C 1 -C 4 )alkynyl, (C 1 -C 4 )perfluoroalkyl, perfluoro(C 1 -C 4 )alkoxy, R 18 —, R 18 —O—, R 18 —(C 1 -C 4 )alkyl-O—, R 18 —(C═O)—, R 18 —(C═O)—O—, R 18 —O—(C═O)— R 18 —S—, R 22 —(S═O)—, R 18 —(SO 2 )—, R 22 —(SO 2 )—(NR 21 )—, R 19 —(C═O)—(NR 21 )—, R 22 —O—(C═O)—(NR 21 )—, (R 19 R 20 )N—, (R 19 R 20 )N—(SO 2 )—, (R 19 R 20 )N—(C═O)—; (R 19 R 20 )N—(C═O)—(NR 21 )— and (R 19 R 20 )N—(C═O)—O—;  
         each of R 16  and R 17  are independently selected from hydrogen and (C 1 -C 4 )alkyl;  
         or R 16  and R 17  may optionally be taken together with the carbon to which they are attached to form a 5 to 10-membered carbocyclic ring;  
         R 16 , R 19 , R 20  and R 21  are independently selected from the group consisting of hydrogen, (C 1 -C 4 )alkyl, (C 6 -C 10 )aryl, (C 3 -C 8 )cycloalkyl, (C 1 -C 10 )heteroaryl and (C 1 -C 10 )heterocyclyl; wherein said (C 6 -C 10 )aryl, (C 3 -C 8 )cycloalkyl, (C 1 -C 10 )heteroaryl and (C 1 -C 10 )heterocyclyl moieties may be optionally substituted on any of the ring carbon atoms capable of forming an additional bond by one to three substituents per ring independently selected from F, Cl, Br, CN, OH, (C 1 -C 4 )alkyl, (C 1 -C 4 )perfluoroalkyl, (C 1 -C 4 )perfluoroalkoxy, (C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkyl-N H—, [(C 1 -C 4 )alkyl] 2 —N— and (C 3 -C 8 )cycloalkyloxy; wherein said (C 3 -C 8 )cycloalkyl and (C 1 -C 10 )heterocyclyl moieties may also optionally be substituted by oxo; wherein said (C 1 -C 10 )heteroaryl and (C 1 -C 10 )heterocyclyl moieties may optionally be substituted on any ring nitrogen atom able to support an additional substituent by one to two substituents per ring independently selected from the group consisting of (C 1 -C 4 )alkyl and (C 1 -C 4 )alkyl-(C═O)—;  
         or R 19  and R 20  may optionally be taken together with the nitrogen to which they are attached to form a 3 to 8-membered heterocyclic ring;  
         or R 19  and R 21  may optionally be taken together with the nitrogen, the carbon or the oxygen to which they are attached to form a 3 to 8-membered heterocyclic ring;  
         R 22  is selected from the group consisting of (C 1 -C 4 )alkyl, (C 6 -C 10 )aryl, (C 3 -C 8 )cycloalkyl, (C 1 -C 10 )heteroaryl and (C 1 -C 10 )heterocyclyl; wherein said (C 6 -C 10 )aryl, (C 3 -C 8 )cycloalkyl, (C 1 -C 10 )heteroaryl and (C 1 -C 10 )heterocyclyl moieties may be optionally substituted on any of the ring carbon atoms capable of forming an additional bond by one to three substituents per ring independently selected from F, Cl, Br, CN, OH, (C 1 -C 4 )alkyl, (C 1 -C 4 )perfluoroalkyl, (C 1 -C 4 )perfluoroalkoxy, (C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkyl-NH—, [(C 1 -C 4 )alkyl] 2 —N— and (C 3 -C 8 )cycloalkyloxy; wherein said (C 3 -C 8 )cycloalkyl and (C 1 -C 10 )heterocyclyl moieties may also optionally be substituted by oxo; wherein said (C 1 -C 10 )heteroaryl and (C 1 -C 10 )heterocyclyl moieties may optionally be substituted on any ring nitrogen atom able to support an additional substituent by one to two substituents per ring independently selected from the group consisting of (C 1 -C 4 )alkyl and (C 1 -C 4 )alkyl-(C═O)—;  
         or R 21  and R 22  may optionally be taken together with the nitrogen, the oxygen or the sulfur to which they are attached to form a 3 to 8-membered heterocyclic ring;  
         or a pharmaceutically acceptable salt thereof.  
       
     
     
         2 . The compound according to  claim 1  wherein said “A” is  
       
         
           
           
               
               
           
         
       
     
     
         3 . The compound according to  claim 1  wherein said “A” is  
       
         
           
           
               
               
           
         
       
     
     
         4 . The compound according to  claim 1  wherein said “A” is  
       
         
           
           
               
               
           
         
       
     
     
         5 . The compound according to  claim 1  wherein said “A” is  
       
         
           
           
               
               
           
         
       
     
     
         6 . The compound according to  claim 1  wherein said X is (C 6 -C 10 )aryl.  
     
     
         7 . The compound according to  claim 1  wherein said X is phenyl.  
     
     
         8 . The compound according to  claim 1  wherein said X is (C 1 -C 10 )heteroaryl selected from the group consisting of benzimidazolyl, benzofuranyl, benzofurazanyl, 2H-1-benzopyranyl, benzothiadiazine, benzothiazinyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, chromanyl, cinnolinyl, furazanyl, furopyridinyl, furyl, imidazolyl, indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrazolyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrazolyl, thiazolyl, thiadiazolyl, thienyl, triazinyl and triazolyl, wherein said (C 1 -C 10 )heteroaryl is optionally substituted on any of the ring carbon atoms capable of forming an additional bond by one or two substituents per ring independently selected from F, Cl, Br, CN, OH, (C 1 -C 4 )alkyl, (C 1 -C 4 )perfluoroalkyl, (C 1 -C 4 )perfluoroalkoxy, (C 1 -C 4 )alkoxy and (C 3 -C 8 )cycloalkyloxy.  
     
     
         9 . The compound according to  claim 1  wherein said Y is oxygen.  
     
     
         10 . The compound according to  claim 1  wherein said Z is selected from the group consisting of (C 6 -C 10 )aryl or (C 1 -C 10 )heteroaryl; wherein said Z may be optionally substituted on any of the ring carbon atoms capable of forming an additional bond by one or two substituents per ring independently selected from F, Cl, Br, CN, OH, (C 1 -C 4 )alkyl, (C 1 -C 4 )perfluoroalkyl, (C 1 -C 4 )perfluoroalkoxy, (C 1 -C 4 )alkoxy and (C 3 -C 8 )cycloalkyloxy.  
     
     
         11 . The compound according to  claim 1  wherein said G is R 15 —(CR 1 , R 17 ) p —; wherein p is 0.  
     
     
         12 . The compound according to  claim 11 , wherein said R 15  is selected from the group consisting of hydrogen, —CN, halo and oxadiazolyl.  
     
     
         13 . The compound according to  claim 1  wherein said G is R 15 —(CR 16 R 17 ) p —; wherein p is an integer from 1 to 4.  
     
     
         14 . The compound according to  claim 1 , wherein R 15  is selected from the group consisting of (C 1 -C 10 )heteroaryl; R 19 —(C═O)—(NR 21 )—, (R 19 R 20 )N—, (R 19 R 20 )N—(C═O)—(NR 21 )— and R 22 —O—(C═O)—(NR 21 ); 
 each of R 16  and R 17  are independently hydrogen or (C 1 -C 4 )alkyl;    R 19  is (C 1 -C 4 )alkyl or (C 3 -C 8 )cycloalkyl;    R 20  is hydrogen or (C 1 -C 10 )heteroaryl selected from the group consisting of 2-oxazolyl, 2-pyrazolyl and 3-pyrazolyl;    R 21  is hydrogen or (C 1 -C 4 )alkyl; and    R 22  is (C 1 -C 4 )alkyl or (C 3 -C 8 )cycloalkyl.    
     
     
         15 . The compound according to  claim 1 , wherein R 15  has the formula R 19 —(C═O)—(NR 21 )—; each of R 16  and R 17  are independently hydrogen or (C 1 -C 4 )alkyl; R 19  is selected from the group consisting of methyl, ethyl, propyl, butyl and cyclobutyl; and R 21  is hydrogen.  
     
     
         16 . The compound according to  claim 1 , wherein R 15  is selected from the group consisting of (R 19 R 20 )N—, (R 19 R 20 )N—(SO 2 )—, (R 19 R 20 )N—(C═O)—; (R 19 R 20 )N—(C═O)—(NR 21 )— and (R 19 R 20 )N—(C═O)—O—; wherein R 19  and R 20  are taken together with the nitrogen to which they are attached to form a 3 to 8-membered heterocyclic ring.  
     
     
         17 . The compound according to  claim 1 , wherein R 15  is selected from the group consisting of R 19 —(C═O)—NR 21 —; R 22 —(SO 2 )—NR 21 —; R 22 —O—(C═O)—(NR 21 ) and (R 19 R 20 )N—(C═O)—NR 2 —; 
 each of R 16  and R 17  are independently hydrogen or (C 1 -C 4 )alkyl;    R 19  and R 21  are taken together with the nitrogen, the carbon or the oxygen to which they are attached to form a 3-8 membered heterocyclic ring; and    R 21  and R 22  are taken together with the nitrogen, the carbon or the oxygen to which they are attached to form a 3-8 membered heterocyclic ring.    
     
     
         18 . The compound according to  claim 1 , which is 1-[6-(4-Fluoro-phenoxy)-pyridin-3-yl]-1,8,10-triaza-spiro[5.5]undecane-2,7,9,11-tetraone; or a pharmaceutically acceptable salt thereof.  
     
     
         19 . A method for treating a condition selected from the group consisting of connective tissue disorders, inflammatory disorders, immunology/allergy disorders, infectious diseases, respiratory diseases, cardiovascular diseases, eye diseases, metabolic diseases, central nervous system disorders, liver/kidney diseases, reproductive health disorders, gastric disorders, skin disorders and cancers in a mammal, including a human, comprising administering to said mammal an amount of a compound of  claim 1 , effective in treating such a condition.  
     
     
         20 . A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of  claim 1  and a pharmaceutically acceptable carrier.